Article
Cell Biology
Xuehong Wang, Zhidong Qiu, Wei Dong, Zebin Yang, Junnan Wang, Hailiang Xu, Tian Sun, Zhaoquan Huang, Junfei Jin
Summary: S1PR1 is highly expressed in the blood vessels of hepatocellular carcinoma (HCC) tissues and promotes angiogenesis by upregulating the expression of proangiogenic factors. It also inhibits CerS3 transcription by inducing CerS6 nuclear translocation. Lenvatinib downregulates S1PR1 expression and enhances its knockdown-mediated angiogenesis inhibition, making it a potential therapy for HCC.
CELL DEATH & DISEASE
(2022)
Review
Immunology
Ping Yu, Yaru Wang, Dahai Yuan, Yunqin Sun, Shuang Qin, Tianye Li
Summary: The review provides a comprehensive overview of vascular normalization and its potential implications in ovarian cancer. The evidence suggests that vascular normalization therapy is a promising approach that can modify the tumor microenvironment, enhance anti-tumor immunity, and synergize with immunotherapy. This review contributes to the growing body of knowledge supporting the utilization of combination therapy as a promising treatment paradigm for ovarian cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Engineering, Biomedical
Changhao Li, Cairong Xiao, Lizhen Zhan, Zhekun Zhang, Jun Xing, Jinxia Zhai, Zhengnan Zhou, Guoxin Tan, Jinhua Piao, Yahong Zhou, Suijian Qi, Zhengao Wang, Peng Yu, Chengyun Ning
Summary: This study proposes a wireless electrical stimulation strategy to achieve tumor vascular normalization by breaking bioelectric homeostasis within cells. Polarized barium titanate nanoparticles with high mechano-electrical conversion performance are developed, which can generate pulsed open-circuit voltage under low-intensity pulsed ultrasound. Wireless electrical stimulation significantly inhibits endothelial cell migration and differentiation in vitro. In vivo experiments show that wireless electrical stimulation normalizes tumor vasculature by optimizing vascular structure, enhancing blood perfusion, reducing vascular leakage, and restoring local oxygenation.
BIOACTIVE MATERIALS
(2022)
Article
Oncology
Jing Zhou, Xuejing Shi, Shulan Hao, Fupeng Zhang, Zhi Guo, Yu Gao, Hao Guo, Likun Liu
Summary: The study demonstrated the potential anti-angiogenesis and vessel normalization effects of ORI, which may be mediated partly by suppressing the JAK2/STAT3 signaling pathway. The results also suggest an optimal time point for ORI therapy in conjunction with chemoradiotherapy or immunotherapy.
Article
Biochemistry & Molecular Biology
Eiko Taguchi, Keisuke Horiuchi, Akira Senoo, Michiro Susa, Masahiro Inoue, Takahiro Ishizaka, Hajime Rikitake, Yusuke Matsuhashi, Kazuhiro Chiba
Summary: Eribulin, a novel microtubule inhibitor, not only induces apoptosis by inhibiting mitotic division of cells, but also has the potential to induce tumor vascular remodeling through mechanisms such as intussusceptive angiogenesis. It exhibits potent antitumor activity against synovial sarcoma and leads to the formation of intervascular pillars in tumor vessels, suggesting a previously unacknowledged role of intussusceptive angiogenesis in regulating tumor vasculature after eribulin administration.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Cell Biology
Guangxin Li, Jiajia Hu, Christina Cho, Junwei Cui, Ao Li, Pengwei Ren, Jichun Zhou, Wei Wei, Tianxiang Zhang, Xiaoling Liu, Weiru Liu
Summary: Triple-negative breast cancer (TNBC) is a challenging subtype to treat due to lack of targetable receptors. The mTOR signaling pathway has been implicated in TNBC and mTOR inhibition is considered a potential therapeutic strategy. However, the efficacy of mTOR inhibitor everolimus (EVE) in TNBC is still unclear. In this study, we found that EVE monotherapy inhibited mTOR signaling but did not slow tumor progression. Additionally, EVE treatment led to abnormal tumor vasculature and increased PD-L1 expression, resulting in reduced CD8+ T cell infiltration. Combination treatment with anti-PD-1 antibody and EVE normalized tumor vasculature, restored CD8+ T cell infiltration, and reduced tumor growth. Our findings provide insights into mTOR inhibition resistance and propose a novel combination treatment strategy for mTOR resistant TNBC tumors.
CELLULAR SIGNALLING
(2023)
Article
Cell Biology
Wang-Dong Xu, Lin-Chong Su, Lu Fu, You-Yu Lan, Xiao-Yan Liu, Qi Huang, Qian Wu, Jie Zhou, An-Fang Huang
Summary: IL-38 regulates the pathogenesis of SLE and targeting IL-38 is critical in the treatment of SLE.
INFLAMMATION RESEARCH
(2022)
Article
Immunology
Peng Fan, Huiping Qiang, Zhenhua Liu, Qi Zhao, Ying Wang, Tingkun Liu, Xuan Wang, Tianqing Chu, Yuhui Huang, Wei Xu, Songbing Qin
Summary: This study found that effective low-dose Anlotinib can inhibit tumor growth while reducing side effects. Low-dose Anlotinib treatment can durably normalize tumor vasculature and improve the efficacy of anti-PD-1 therapy. The combination therapy increases the proportions of intratumoral CD4(+) T, CD8(+) T, and NK cells, and requires CD8(+) T cells to suppress tumor growth. The results suggest that the combination of effective low-dose Anlotinib and PD-1 blockade is more effective and safer for achieving antitumor effects.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xue Sun, Yue Dai, Jing He, Hongchen Li, Xuhui Yang, Wenjing Dong, Xiao Xie, Mingsong Wang, Yanping Xu, Lei Lv
Summary: D-mannose up-regulates lysosomal activity, enhances degradation of EGFR, and significantly inhibits proliferation and tumor growth of NSCLC cells both in vitro and in vivo. Hence, D-mannose may represent a novel strategy for clinical treatment of NSCLC.
Article
Biochemistry & Molecular Biology
Min-Hee Jo, Yong-Tae Kim, Sun Joo Park
Summary: Dieckol, a natural polyphenol, inhibits the growth of melanoma cells by inducing apoptotic cell death through affecting lysosomal function and mitochondrial membrane. This suggests its potential value as a chemotherapeutic drug candidate for melanoma treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Medicinal
Yu-Kai Su, Oluwaseun Adebayo Bamodu, I-Chang Su, Narpati Wesa Pikatan, Iat-Hang Fong, Wei-Hwa Lee, Chi-Tai Yeh, Hsiao-Yean Chiu, Chien-Min Lin
Summary: The study evaluated the effects of BTK and mTOR inhibition on glioblastoma (GBM) and found a synergistic relationship between acalabrutinib and rapamycin, which effectively suppressed CSC phenotypes and angiogenesis potential, promoting vascular normalization for chemoresistant/radioresistant GBM.
Article
Multidisciplinary Sciences
Valentin-Florian Rauca, Laura Patras, Lavinia Luput, Emilia Licarete, Vlad-Alexandru Toma, Alina Porfire, Augustin Catalin Mot, Elena Rakosy-Tican, Alina Sesarman, Manuela Banciu
Summary: The novel combination tumor-targeted treatment shows significant inhibitory effects on melanoma growth by enhancing anti-angiogenic effects and inducing apoptosis of tumor cells, with the potential to remodel the tumor microenvironment.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Jia Xu, Xufen Yu, Tiphaine C. Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M. Cahuzac, Li Wang, Ling Xie, Royce Zhou, Yudao Shen, Xuewei Wu, Shen Yao, Ruifang Qiao, Poulikos Poulikakos, Xian Chen, Jing Liu, Jian Jin, Ramon Parsons
Summary: Through degrading AKT and AURKB proteins, MS21 can inhibit tumor growth, especially in patients with mutations in the PI3K-PTEN pathway but not the RAS pathway.
Article
Plant Sciences
Ying Liu, Xiaobei Liu, Hui Wang, Pingping Ding, Changlin Wang
Summary: Agrimonolide induces apoptosis and ferroptosis by targeting SCD1 in ovarian cancer cells, demonstrating its anticancer activity. Agrimonolide may serve as a novel therapeutic agent for treating ovarian cancer.
Article
Biochemistry & Molecular Biology
Yi-Ting Chen, Tzu-Ting Tseng, Hung-Pei Tsai, Ming-Yii Huang
Summary: Arylquin 1 exhibits anticancer effects in colorectal cancer cells by inhibiting cell proliferation, migration, and invasion, and inducing apoptosis. It increases the phosphorylation levels of ERK, JNK, and p38, which are related to key signaling proteins.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Robert L. Gottlieb, Ajay Nirula, Peter Chen, Joseph Boscia, Barry Heller, Jason Morris, Gregory Huhn, Jose Cardona, Bharat Mocherla, Valentina Stosor, Imad Shawa, Princy Kumar, Andrew C. Adams, Jacob Van Naarden, Kenneth L. Custer, Michael Durante, Gerard Oakley, Andrew E. Schade, Timothy R. Holzer, Philip J. Ebert, Richard E. Higgs, Nicole L. Kallewaard, Janelle Sabo, Dipak R. Patel, Paul Klekotka, Lei Shen, Daniel M. Skovronsky
Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Peter Chen, Ajay Nirula, Barry Heller, Robert L. Gottlieb, Joseph Boscia, Jason Morris, Gregory Huhn, Jose Cardona, Bharat Mocherla, Valentina Stosor, Imad Shawa, Andrew C. Adams, Jacob Van Naarden, Kenneth L. Custer, Lei Shen, Michael Durante, Gerard Oakley, Andrew E. Schade, Janelle Sabo, Dipak R. Patel, Paul Klekotka, Daniel M. Skovronsky
Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cell Biology
Timothy B. Branigan, David Kozono, Amy E. Schade, Peter Deraska, Hembly G. Rivas, Larissa Sambel, Hunter D. Reavis, Geoffrey Shapiro, Alan D. D'Andrea, James A. DeCaprio
Summary: This study identified that knockout of MMB-FOXM1 complex components LIN54 and FOXM1 reduced CHK1 inhibitor-induced DNA replication stress markers and premature mitosis during Late S phase. Activation of a feedback loop between the MMB-FOXM1 complex and CDK1 is required for CHK1 inhibitor-induced premature mitosis in Late S phase and subsequent replication catastrophe. These findings offer mechanistic insights into small molecule inhibitors under clinical trials and support combination therapies.
Article
Oncology
Ioannis A. Vathiotis, Tyler MacNeil, Jon Zugazagoitia, Konstantinos N. Syrigos, Thazin Nwe Aung, Aaron M. Gruver, Peter Vaillancourt, Ina Hughes, Steve Hinton, Kyla Driscoll, David L. Rimm
Summary: The study revealed that the CD200/CD200R immune checkpoint is widely expressed in lung cancer patients and may serve as a potential target for immune therapy. Both CD200 and CD200R are abundantly expressed in NSCLC patients, with moderate correlation with PD-L1. This finding provides a basis for targeting the CD200/CD200R pathway for treating NSCLC patients.
Article
Pathology
Armando R. Irizarry Rovira, Kim G. Hilbish, Matthew Schroeder, Gary A. Boorman, Kelly M. Credille, Darryl Ballard, Jeff C. Hanson, Andrea Niedenthal
Summary: The study found that daily gavage administration of vehicle formulations containing SLS can cause respiratory injury and a mortality rate of 14% in male CD-1 mice.
TOXICOLOGIC PATHOLOGY
(2021)
Article
Medical Laboratory Technology
Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
Summary: This study validated and described the performance of Abbott Molecular RET break-apart FISH probes for detecting RET rearrangements. The results showed that using appropriate cutoffs can achieve high sensitivity and specificity. This helps to ensure that appropriate patients receive effective, timely therapy.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Article
Medicine, General & Internal
Hiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, Kentaro Yamazaki, Andrew B. Nixon, Josep Tabernero, Eric Van Cutsem, Kim R. Robling, Paolo B. Abada, Rebecca R. Hozak, Robert Siegel, Jeffrey A. Fill, Sameera Wijayawardana, Richard A. Walgren, Brendan Giles, Abby Jones, Kelly R. Pitts, Nora Drove, Kei Muro
Summary: A new plasma detection method was used to investigate the relationship between Vascular endothelial growth factor (VEGF)-D levels and the efficacy of ramucirumab in treating metastatic colorectal cancer. The study found that patients with high VEGF-D levels had better overall survival and progression-free survival when treated with ramucirumab compared to placebo, but baseline VEGF-D levels were not predictive of the benefit of ramucirumab in terms of overall survival.
CURRENT MEDICAL RESEARCH AND OPINION
(2021)
Article
Pathology
Aaron M. Gruver, Matt D. Westfall, Bradley L. Ackermann, Salisha Hill, Ryan D. Morrison, Juraj Bodo, Keith K. Lai, David C. Gemperline, Eric D. Hsi, Daniel C. Liebler, Jochen Schmitz, Robert J. Benschop
Summary: This study successfully used targeted mass spectrometry to analyze the expression of various cells and proteins in 19 ulcerative colitis (UC) biopsies, and performed global proteome analysis to identify pathways associated with UC progression. Positive correlations were observed between histological scores of active colitis and certain measurements, while inverse relationships were detected with other targets due to crypt disruption. An exploratory accuracy assessment showed promising sensitivities and specificities with established cut-offs. Further studies are needed to verify the utility of this novel approach.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Medicine, General & Internal
M. Dougan, A. Nirula, M. Azizad, B. Mocherla, R. L. Gottlieb, P. Chen, C. Hebert, R. Perry, J. Boscia, B. Heller, J. Morris, C. Crystal, A. Igbinadolor, G. Huhn, J. Cardona, I Shawa, P. Kumar, A. C. Adams, J. Van Naarden, K. L. Custer, M. Durante, G. Oakley, A. E. Schade, T. R. Holzer, P. J. Ebert, R. E. Higgs, N. L. Kallewaard, J. Sabo, D. R. Patel, M. C. Dabora, P. Klekotka, L. Shen, D. M. Skovronsky
Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Michael Dougan, Masoud Azizad, Bharat Mocherla, Robert L. Gottlieb, Peter Chen, Corey Hebert, Russell Perry, Joseph Boscia, Barry Heller, Jason Morris, Chad Crystal, Awawu Igbinadolor, Gregory Huhn, Jose Cardona, Imad Shawa, Princy Kumar, Andra Blomkalns, Andrew C. Adams, Jacob Van Naarden, Kenneth L. Custer, Jack Knorr, Gerard Oakley, Andrew E. Schade, Timothy R. Holzer, Philip J. Ebert, Richard E. Higgs, Janelle Sabo, Dipak R. Patel, Matan C. Dabora, Mark Williams, Paul Klekotka, Lei Shen, Daniel M. Skovronsky, Ajay Nirula
Summary: Bamlanivimab and etesevimab together (700/1400 mg) reduced hospitalizations and viral load in patients with mild-to-moderate COVID-19.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Anatomy & Morphology
Monika D. Polewski, Gitte B. Nielsen, Ying Gu, Aaron T. Weaver, Gavin Gegg, Siena Tabuena-Frolli, Mariana Cajaiba, Debra Hanks, Michael Method, Michael F. Press, Claudia Gottstein, Aaron M. Gruver
Summary: The objective of this study was to develop a standardized Ki-67 immunohistochemistry method for precise assessment of patients with early breast cancer and to evaluate the prognostic value of Ki-67 expression in these patients. The results showed that patients with high Ki-67 expression had a higher risk of developing invasive disease within 2 years compared to those with low Ki-67 expression.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2022)
Article
Medicine, Research & Experimental
Jonathan T. Sims, Josh Poorbaugh, Ching-Yun Chang, Timothy R. Holzer, Lin Zhang, Sarah M. Engle, Stephanie Beasley, Thompson N. Doman, Lynn Naughton, Richard E. Higgs, Nicole Kallewaard, Robert J. Benschop
Summary: This study aimed to monitor and characterize the immune response to SARS-CoV-2 infection in hospitalized patients with COVID-19 through analysis of peripheral blood and nasopharyngeal swab samples, with or without bamlanivimab treatment. The findings showed elevated levels of certain inflammatory protein biomarkers in the serum of COVID-19 patients, which were linked with inflammatory and viral-induced interferon response genes detected in nasopharyngeal swab samples.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Anatomy & Morphology
Miglena Komforti, Erinn Downs-Kelly, Francisco Sapunar, Sameera R. Wijayawardana, Aaron M. Gruver, Sunil S. Badve
Summary: This study compared the concordance of Ki-67 immunohistochemistry results obtained from different automated staining instruments on breast cancer samples and found that good concordance can be achieved with reagents run on the ASL48 instrument, demonstrating the importance of optimized protocols and standardized scoring.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2022)
Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner, Francisco Sapunar
Summary: This study assessed the correlation between Oncotype Dx (R) assay and Ki-67 IHC MIB-1 assay. The results showed a moderately positive correlation, suggesting that they should not be used interchangeably in clinical practice.
BREAST CANCER RESEARCH
(2022)